Archives

by in
Entry Author Date Location
Dendritic Nanotechnologies Focuses Dendrimer Development On Industry Rather Than Pharma 05/07/10 Detroit
Averting “Disaster” in Healthcare: Xconomy Forum at MIT Tackles Big Problems and Potential Technology Fixes 04/28/10 Boston
Technology Alliance Showcases Five Companies in Sensors, Mobile Displays, and Drug Therapies: Investors Take Notice 04/22/10 Seattle
Anadys Reports Interim Hep C Drug Data, Ligand Collects Milestone Payment, Phenomix’s Diabetes Drug Shows Promise, & More San Diego Life Sciences News 04/22/10 San Diego
Amplyx Pharmaceuticals, Led By Women, Builds Platform for Improving Drugs for HIV, Cancer 04/20/10 San Diego
U.S. Chief Humanitarian: We Want to Buy Your Health Products For Poor Countries 03/17/10 Seattle
Genetix Pharma Raises $35M from Third Rock, Genzyme for Gene Therapy 03/12/10 Boston
Vertex Maps Out Combo Drug Game Plan for Treating Hepatitis C 03/08/10 Boston
Una Ryan Searching for Riches to Deliver Inexpensive Diagnostics to the Poor 03/05/10 Boston
Anadys Hepatitis C Drug Increases Punch Over Time (But So Does Placebo) 02/24/10 San Diego
Gilead Sciences Gets FDA Green Light To Sell Cystic Fibrosis Drug 02/23/10 Seattle
NanoString Chairman Bill Young Scopes Out Diagnostic Future, Considers Bay Area Expansion 02/19/10 Seattle
Bill Gates Posts Annual Letter, Backs Khosla 01/25/10 Seattle
Gilead Deepens Roots in Seattle, Seeks Long-Term Payoff From Lung Disease Research 01/13/10 Seattle
Lycera, a Midwestern Biotech Star, Moves Head Office to Boston, Hires Biogen Vet as CEO 01/07/10 Boston
The 12 Days of Xconomists: Leading Innovators Give Their Top Advances of the Past Decade 01/05/10 National
Top Five Medical Innovations of the 2000s (And One Big Concern) 12/29/09 National
The Top Five Biotech Innovations of the 2000s 12/15/09 Seattle
Seattle’s Kineta Rakes in Half of $13M Federal Contract to UW For Vaccine Boosters 11/10/09 Seattle
Concert Starts HIV Trial, Bags $12M From Glaxo to Help Challenge Gilead’s Once-Daily Pill 11/09/09 Boston
Combination Drugs Are The Future for Hepatitis C 11/03/09 San Diego
UW Scientists, Backed by Gates Foundation, Enter “Put Up or Shut Up” Phase with Portable Diagnostic 11/03/09 Seattle
Virdante Pharma Lands $30M in A Round to Combat Inflammation 10/29/09 Boston
Vertex Hepatitis C Drug Wipes Out Virus For Toughest-to-Treat Patients 10/28/09 Boston
San Diego’s Ardea Biosciences Sees Potential for Gout Drug in Combination Treatment 10/19/09 San Diego
Omeros Accused on Eve of IPO, Seattle Genetics Trial Fails, How Much Biotechies Really Earn, & More Seattle-Area Life Sciences News 10/08/09 Seattle
Seattle’s Theraclone Strikes $18M Deal to Make Flu-Fighting Antibodies with Japanese Company 10/05/09 Seattle
AVI Settles In, ZymoGenetics MS Drug Fails, Dendreon’s FDA Filing Set for Mid-November & More Seattle-Area Life Sciences News 10/01/09 Seattle
The Quest for an HIV Vaccine 09/29/09 Seattle
Targeted Genetics Lives On, CellCyte Charged With Fraud, Theraclone Finds HIV Weakness, & More Seattle-Area Life Sciences News 09/10/09 Seattle
Page 3 of 5 « previous page · next page »

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  3. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  4. Do You Need an Extended Warranty? Do the Math, Says SquareTrade
  5. Announcing Xconomy Napa Summit 2013: New Rules for Growth

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.